Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (169)	8/8/2006 2:33:41 PM
From: rkrw	Read Replies (1) \| Respond to of 3027

Only negatives I saw, burn rate now at higher end of $30-40M range but that doesn't account for the nvs deal and is the two part trial negative since if they fail to overturn on phase I, it takes longer to get through phase II? Hypothetical non lawyer questions. Same inequitable conduct issue as before, same judge who ruled the first time, same appeals court, what and how will the inequitable conduct outcome (and reversal) change? If it's all the same info as before and the judge places a higher burden of proof, is she likely to rule no on inequitable conduct? Hard to imagine why the deal wouldn't pass Scott Hart Rodino. But I've noticed Crane enjoys explaining the downside risks more than other bio ceo's.